Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination.
Ann Neurol
; 90(2): 315-318, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1330296
ABSTRACT
Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain-Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine. This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS-CoV-2 and that postvaccination surveillance programs ensure robust data capture of this outcome, to assess for causality. ANN NEUROL 2021;90315-318.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Guillain-Barre Syndrome
/
COVID-19 Vaccines
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Vaccines
/
Variants
Limits:
Adult
/
Humans
/
Male
/
Middle aged
/
Young adult
Language:
English
Journal:
Ann Neurol
Year:
2021
Document Type:
Article
Affiliation country:
Ana.26144
Similar
MEDLINE
...
LILACS
LIS